{"doi":"10.1101/2022.01.10.22268752","title":"Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study","abstract":"Abstract Objective To determine the impact of MS disease-modifying therapies (DMTs) on the development of cellular and humoral immunity to SARS-CoV-2 infection. Methods MS patients aged 18-60 were evaluated for anti-nucleocapsid and anti-Spike RBD antibody with electro-chemiluminescence immunoassay; antibody responses to Spike protein, RBD, N-terminal domain with multiepitope bead-based immunoassays (MBI); live virus immunofluorescence-based microneutralization assay; T-cell responses to SARS-CoV-2 Spike using TruCulture ELISA; and IL-2 and IFNγ ELISpot assays. Assay results were compared by DMT class. Spearman correlation and multivariate analyses were performed to examine associations between immunologic responses and infection severity. Results Between 1/6/2021 and 7/21/2021, 389 MS patients were recruited (mean age 40.3 years; 74% female; 62% non-White). Most common DMTs were ocrelizumab (OCR) - 40%; natalizumab - 17%, Sphingosine 1-phosphate receptor (S1P) modulators −12%; and 15% untreated. 177 patients (46%) had laboratory evidence of SARS-CoV-2 infection; 130 had symptomatic infection, 47 - asymptomatic. Antibody responses were markedly attenuated in OCR compared to other groups (p≤ 0001). T-cell responses (IFNγ were decreased in S1P (p=0.03), increased in natalizumab (p<0.001), and similar in other DMTs, including OCR. Cellular and humoral responses were moderately correlated in both OCR (r=0.45, p=0.0002) and non-OCR (r=0.64, p<0.0001). Immune responses did not differ by race/ethnicity. COVID-19 clinical course was mostly non-severe and similar across DMTs; 7% (9/130) were hospitalized. Interpretation DMTs had differential effects on humoral and cellular immune responses to SARS-CoV-2 infection. Immune responses did not correlate with COVID-19 clinical severity in this relatively young and non-disabled group of MS patients.","journal":"medRxiv","year":2022,"id":298508,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9669,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":918169,"name":"Y. Patskovsky","orcid":"0000-0003-3316-2295","position":1,"is_corresponding":false},{"id":918859,"name":"Ryan Curtin","orcid":null,"position":2,"is_corresponding":false},{"id":913846,"name":"Jinglan Pei","orcid":null,"position":3,"is_corresponding":false},{"id":687402,"name":"Katherine Perdomo","orcid":null,"position":4,"is_corresponding":false},{"id":643692,"name":"Zoe Rimler","orcid":null,"position":5,"is_corresponding":false},{"id":918860,"name":"Iryna Voloshyna","orcid":null,"position":6,"is_corresponding":false},{"id":550603,"name":"Marie I. Samanovic","orcid":"0000-0002-6987-2232","position":7,"is_corresponding":false},{"id":710782,"name":"Amber Cornelius","orcid":null,"position":8,"is_corresponding":false},{"id":918167,"name":"Yogambigai Velmurugu","orcid":"0000-0001-6418-1048","position":9,"is_corresponding":false},{"id":918168,"name":"Samantha Nyovanie","orcid":"0000-0003-0966-0024","position":10,"is_corresponding":false},{"id":918166,"name":"Joseph Kim","orcid":"0000-0002-9251-2956","position":11,"is_corresponding":false},{"id":918861,"name":"Ethan Tardio","orcid":null,"position":12,"is_corresponding":false},{"id":918165,"name":"Tamar Bacon","orcid":"0000-0002-5118-8977","position":13,"is_corresponding":false},{"id":987559,"name":"Lana Zhovtis Ryerson","orcid":"0000-0003-1868-3893","position":14,"is_corresponding":false},{"id":918865,"name":"Pranil Raut","orcid":null,"position":15,"is_corresponding":false},{"id":987921,"name":"Rosetta Pedotti","orcid":null,"position":16,"is_corresponding":false},{"id":987922,"name":"Kathleen Hawker","orcid":null,"position":17,"is_corresponding":false},{"id":884347,"name":"Catarina Raposo","orcid":"0000-0002-1466-1542","position":18,"is_corresponding":false},{"id":913847,"name":"Jessica Priest","orcid":null,"position":19,"is_corresponding":false},{"id":918866,"name":"Mark Cabatingan","orcid":null,"position":20,"is_corresponding":false},{"id":913223,"name":"Ryan C. Winger","orcid":"0000-0001-9160-6646","position":21,"is_corresponding":false},{"id":3883,"name":"Mark J. Mulligan","orcid":"0000-0001-7262-9746","position":22,"is_corresponding":false},{"id":826969,"name":"Michelle Krogsgaard","orcid":"0000-0001-5006-7981","position":23,"is_corresponding":false},{"id":447495,"name":"Gregg J. Silverman","orcid":"0000-0001-9480-9457","position":24,"is_corresponding":false},{"id":529976,"name":"Ilya Kister","orcid":"0000-0003-3549-949X","position":0,"is_corresponding":true}],"reference_count":53,"raw_metadata":null,"created_at":"2026-07-19T00:31:36.269611Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}